Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen and Aspirin with AC-T in ER+/HER2- Breast Cancer
NCT04038489Phase 2Withdrawn
- Sponsor
- University of Virginia
- Start
- Oct 2019
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of aspirin, tamoxifen in breast cancer, sponsored by University of Virginia. Planned start Oct 2019; status: withdrawn.
02
Drugs
aspirintamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04038489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04038489.